News

February 15, 2019February 15, 2019

EMD Serono, GSK Partner to Advance in Trials New Class of Immunotherapy Against Advanced Cancers

News

Merck KGaA and GlaxoSmithKline (GSK) are working together to develop and commercialize the immunotherapy candidate M7824 (bintrafusp alfa) as a potential treatment for multiple, difficult-to-treat types of cancer. M7824 is ... Read more

February 13, 2019

Eureka Plans US Trial Testing ET140202 T-cell Therapy in Liver Cancer Patients

News

Eureka Therapeutics is planning a Phase 1/2 clinical trial in the United States to explore the safety and effectiveness of its investigational T-cell therapy ET140202 in patients with advanced ... Read more

February 12, 2019February 12, 2019

Bavencio Shows Promise in Phase 1 Trial of Heavily Treated Malignant Mesothelioma Patients

News

Immune checkpoint inhibitor Bavencio (avelumab) shows durable clinical activity and long-term disease control among heavily pretreated malignant mesothelioma patients, according to a Phase 1 clinical trial. The treatment — ... Read more

February 8, 2019February 8, 2019

GE Healthcare, Vanderbilt University Medical Center to Develop Apps that Predict Immunotherapy Responses

News

GE Healthcare and Vanderbilt University Medical Center (VUMC) have established a five-year partnership aimed at developing new diagnostic tools to predict how an immunotherapy will work — as far ... Read more

February 6, 2019February 6, 2019

FDA Expands Alimta’s Label for Initial Treatment of Metastatic Lung Cancer

News

The U.S. Food and Drug Administration has expanded Alimta‘s (pemetrexed) label to include a combination with Keytruda (pembrolizumab) and platinum chemotherapy for the initial treatment of certain metastatic non-small cell lung cancer (NSCLC) ... Read more

February 5, 2019February 5, 2019

Phase 1b Trial of ADCT-301 in Advanced Solid Tumors Doses First Patient

News

A Phase 1b clinical trial of ADCT-301 (camidanlumab tesirine) in adult patients with locally advanced or metastatic solid tumors has dosed the first patient. Patient enrollment for this multicenter, ... Read more

February 1, 2019February 1, 2019

Tumors with More Mutations Respond Better to Immunotherapy, Study Suggests

News

A new study suggests that tumors with more mutations respond better to immunotherapy. But determining what constitutes a “high” number of mutations in a given tumor type, and implementing ... Read more

January 30, 2019January 30, 2019

Nanobiotix Plans Nine NBTXR3 Clinical Trials for Six Cancer Types

News

Nanobiotix is planning to conduct nine Phase 1/2 clinical trials in collaboration with the University of Texas MD Anderson Cancer Center to study the company’s investigational compound NBTXR3. The trials, which will ... Read more

January 29, 2019January 29, 2019

Keytruda Reduces Risk of Death in Some Patients with Advanced Esophageal Cancer, Study Shows

News

Second-line treatment with Keytruda (pembrolizumab) significantly extends the lives of advanced esophageal cancer and esophagogastric junction carcinoma patients whose tumors are positive for the PD-L1 factor, a Phase 3 clinical ... Read more

January 25, 2019January 25, 2019

Opdivo-Yervoy Combo Approved in Europe for First-line Treatment of Certain Kidney Cancers

News

The European Commission has approved a combination of Opdivo (nivolumab) and low-dose Yervoy (ipilimumab) for the initial treatment of advanced renal cell carcinoma patients with intermediate and poor risk, ... Read more

Pin It on Pinterest